Payment overview · 2025
General Payments
$433.92
8 reported records · 5 companies
Healthcare provider profile · identity verified
Julie Bryan, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · FORT WAYNE, IN · NPI 1063496644
Verified facts
What the public records show
CMS Open Payments records show Julie Bryan, M.D. received $433.92 in general payments during 2025 across 8 reported records.
Axsome Therapeutics, Inc. accounted for 52.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 82 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $226.08 | 52.1% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $135.70 | 31.3% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $37.23 | 8.6% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $18.15 | 4.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $16.76 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $433.92 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $226.08 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $135.70 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $23.21 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $16.76 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $14.02 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
82 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 808 | 195 |
| Atorvastatin Calcium | Atorvastatin Calcium | 570 | 166 |
| Amlodipine Besylate | Amlodipine Besylate | 552 | 160 |
| Omeprazole | Omeprazole | 550 | 159 |
| Metformin Hcl Er | Metformin Hcl | 344 | 99 |
| Lisinopril | Lisinopril | 316 | 90 |
| Escitalopram Oxalate | Escitalopram Oxalate | 301 | 85 |
| Hydrochlorothiazide | Hydrochlorothiazide | 299 | 81 |
| Pravastatin Sodium | Pravastatin Sodium | 252 | 72 |
| Trazodone Hcl | Trazodone Hcl | 244 | 69 |
| Pregabalin | Pregabalin | 240 | 55 |
| Losartan Potassium | Losartan Potassium | 239 | 64 |
| Gabapentin | Gabapentin | 226 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 217 | 62 |
| Montelukast Sodium | Montelukast Sodium | 216 | 57 |
| Pantoprazole Sodium | Pantoprazole Sodium | 212 | 59 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 212 | 59 |
| Mounjaro | Tirzepatide | 198 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 181 | 35 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 176 | 35 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 172 | 56 |
| Carvedilol | Carvedilol | 156 | 42 |
| Bupropion Xl | Bupropion Hcl | 155 | 46 |
| Irbesartan | Irbesartan | 148 | 42 |
| Allopurinol | Allopurinol | 142 | 33 |
| Sertraline Hcl | Sertraline Hcl | 140 | 40 |
| Tramadol Hcl | Tramadol Hcl | 137 | 37 |
| Simvastatin | Simvastatin | 134 | 37 |
| Famotidine | Famotidine | 133 | 39 |
| Potassium Chloride | Potassium Chloride | 133 | 40 |
| Metformin Hcl | Metformin Hcl | 131 | 39 |
| Ozempic | Semaglutide | 130 | 29 |
| Spironolactone | Spironolactone | 123 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 122 | 38 |
| Torsemide | Torsemide | 121 | 35 |
| Januvia | Sitagliptin Phosphate | 118 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 117 | 30 |
| Furosemide | Furosemide | 113 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 113 | 27 |
| Ezetimibe | Ezetimibe | 111 | 33 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 105 | 35 |
| Prednisone | Prednisone | 105 | 63 |
| Topiramate | Topiramate | 92 | 24 |
| Mirtazapine | Mirtazapine | 91 | 22 |
| Lorazepam | Lorazepam | 90 | 24 |
| Buspirone Hcl | Buspirone Hcl | 88 | 25 |
| Tamsulosin Hcl | Tamsulosin Hcl | 88 | 27 |
| Synthroid | Levothyroxine Sodium | 82 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 81 | 27 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 81 | 23 |
| Meloxicam | Meloxicam | 81 | 31 |
| Alprazolam | Alprazolam | 78 | 21 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 78 | 39 |
| Ropinirole Hcl | Ropinirole Hcl | 77 | 21 |
| Propranolol Hcl Er | Propranolol Hcl | 75 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 19 |
| Jardiance | Empagliflozin | 67 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 18 |
| Glimepiride | Glimepiride | 66 | 17 |
| Atenolol | Atenolol | 65 | 17 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 65 | 20 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 65 | 18 |
| Clonazepam | Clonazepam | 63 | suppressed |
| Ondansetron Odt | Ondansetron | 62 | 34 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 61 | 52 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 61 | 18 |
| Alendronate Sodium | Alendronate Sodium | 60 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 60 | 20 |
| Nebivolol Hcl | Nebivolol Hcl | 59 | 20 |
| Solifenacin Succinate | Solifenacin Succinate | 58 | 19 |
| Tresiba Flextouch U-200 | Insulin Degludec | 57 | suppressed |
| Memantine Hcl | Memantine Hcl | 54 | 14 |
| Nystatin | Nystatin | 54 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | 13 |
| Cephalexin | Cephalexin | 52 | 38 |
| Lamotrigine | Lamotrigine | 52 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 50 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 49 | suppressed |
| Eliquis | Apixaban | 48 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 48 | 13 |
| Valacyclovir | Valacyclovir Hcl | 48 | 17 |
| Celecoxib | Celecoxib | 46 | 14 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 46 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 45 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 43 | 13 |
| Myrbetriq | Mirabegron | 42 | 13 |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Xarelto | Rivaroxaban | 41 | 13 |
| Donepezil Hcl | Donepezil Hcl | 40 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 39 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 39 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 38 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 37 | suppressed |
| Nifedipine Er | Nifedipine | 37 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 37 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 31 | suppressed |
| Glipizide Er | Glipizide | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 31 | 11 |
| Novolog Flexpen | Insulin Aspart | 31 | suppressed |
| Baclofen | Baclofen | 30 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 29 | suppressed |
| Fluconazole | Fluconazole | 29 | 20 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 28 | suppressed |
| Vascepa | Icosapent Ethyl | 28 | suppressed |
| Levetiracetam | Levetiracetam | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 25 | 13 |
| Estradiol | Estradiol | 24 | 14 |
| Ibandronate Sodium | Ibandronate Sodium | 24 | 11 |
| Lansoprazole | Lansoprazole | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 24 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 22 | suppressed |
| Risperidone | Risperidone | 22 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 22 | 19 |
| Hydrocortisone | Hydrocortisone | 21 | 11 |
| Klor-Con M20 | Potassium Chloride | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 20 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 20 | suppressed |
| Amoxicillin | Amoxicillin | 19 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Risedronate Sodium Dr | Risedronate Sodium | 19 | suppressed |
| Tradjenta | Linagliptin | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Zaleplon | Zaleplon | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 18 | suppressed |
| Diazepam | Diazepam | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Epinephrine | Epinephrine | 18 | suppressed |
| Ketoconazole | Ketoconazole | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Ramipril | Ramipril | 18 | suppressed |
| Risedronate Sodium | Risedronate Sodium | 18 | suppressed |
| Linzess | Linaclotide | 17 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 17 | suppressed |
| Lovastatin | Lovastatin | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Methocarbamol | Methocarbamol | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 17 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 16 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Cefdinir | Cefdinir | 15 | 15 |
| Colesevelam Hcl | Colesevelam Hcl | 15 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 15 | suppressed |
| Eplerenone | Eplerenone | 15 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 15 | suppressed |
| Creon | Lipase/Protease/Amylase | 14 | suppressed |
| Indapamide | Indapamide | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Verapamil Er | Verapamil Hcl | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 11 |
| Clonidine | Clonidine | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | 13 |
| Guanfacine Hcl Er | Guanfacine Hcl | 13 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 13 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 13 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Amantadine | Amantadine Hcl | 12 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Xultophy 100-3.6 | Insulin Degludec/Liraglutide | 12 | suppressed |
| Aripiprazole | Aripiprazole | 11 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Levofloxacin | Levofloxacin | 11 | 11 |
| Modafinil | Modafinil | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Primidone | Primidone | 11 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $433.92 · 8 records | Axsome Therapeutics, Inc. | AIRSUPRA, Auvelity, CAPVAXIVE, EVENITY, GARDASIL 9, QULIPTA, REPATHA, UBRELVY | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error